Rhinomed Limited (ASX:RNO, OTCQB: RHNMF), a leader in nasal and respiratory technology and the maker of Mute™ and Pronto™, can report its FY 20 Q4 results and preliminary unaudited full year results. After a record FY20 Q3 result the company was on track to reach its full year planned targets. Confirmation during the quarter that an additional 7,000+ US based stores would begin stocking Rhinomed Technology further supported this positive momentum.
